PMID- 38087705
OWN - NLM
STAT- MEDLINE
DCOM- 20240219
LR  - 20240411
IS  - 1433-2981 (Electronic)
IS  - 0936-6555 (Linking)
VI  - 36
IP  - 3
DP  - 2024 Mar
TI  - Prospective Longitudinal Assessment of Quality of Life After Stereotactic 
      Ablative Radiotherapy for Oligometastases: Analysis of the Population-based 
      SABR-5 Phase II Trial.
PG  - 148-156
LID - S0936-6555(23)00456-9 [pii]
LID - 10.1016/j.clon.2023.11.041 [doi]
AB  - AIMS: To evaluate longitudinal patient-reported quality of life (QoL) in patients 
      treated with stereotactic ablative radiotherapy (SABR) for oligometastases. 
      MATERIALS AND METHODS: The SABR-5 trial was a population-based single-arm phase 
      II study of SABR to up to five sites of oligometastases, conducted in six 
      regional cancer centres in British Columbia, Canada from 2016 to 2020. 
      Prospective QoL was measured using treatment site-specific QoL questionnaires at 
      pre-treatment baseline and at 3, 6, 9, 12, 15, 18, 21, 24, 30 and 36 months after 
      treatment. Patients with bone metastases were assessed with the Brief Pain 
      Inventory (BPI). Patients with liver, adrenal and abdominopelvic lymph node 
      metastases were assessed with the Functional Assessment of Chronic Illness 
      Therapy-Abdominal Discomfort (FACIT-AD). Patients with lung and intrathoracic 
      lymph node metastases were assessed with the Prospective Outcomes and Support 
      Initiative (POSI) lung questionnaire. The two one-sided test procedure was used 
      to assess equivalence between the worst QoL score and the baseline score of 
      individual patients. The mean QoL at all time points was used to determine the 
      trajectory of QoL response after SABR. The proportion of patients with 'stable', 
      'improved' or 'worsened' QoL was determined for all time points based on standard 
      minimal clinically important differences (MCID; BPI worst pain = 2, BPI 
      functional interference score [FIS] = 0.5, FACIT-AD Trial Outcome Index [TOI] = 
      8, POSI = 3). RESULTS: All enrolled patients with baseline QoL assessment and at 
      least one follow-up assessment were analysed (n = 133). On equivalence testing, 
      the patients' worst QoL scores were clinically different from baseline scores and 
      met MCID (BPI worst pain mean difference: 1.8, 90% confidence interval 1.19 to 
      2.42]; BPI FIS mean difference: 1.68, 90% confidence interval 1.15 to 2.21; 
      FACIT-AD TOI mean difference: -8.76, 90% confidence interval -11.29 to -6.24; 
      POSI mean difference: -4.61, 90% confidence interval -6.09 to -3.14). However, 
      the mean FIS transiently worsened at 9, 18 and 21 months but eventually returned 
      to stable levels. The mean FACIT and POSI scores also worsened at 36 months, 
      albeit with a limited number of responses (n = 4 and 8, respectively). Most 
      patients reported stable QoL at all time points (range: BPI worst pain 71-82%, 
      BPI FIS 45-78%, FACIT-AD TOI 50-100%, POSI 25-73%). Clinically significant 
      stability, worsening and improvement were seen in 70%/13%/18% of patients at 3 
      months, 53%/28%/19% at 18 months and 63%/25%/13% at 36 months. CONCLUSIONS: 
      Transient decreases in QoL that met MCID were seen between patients' worst QoL 
      scores and baseline scores. However, most patients experienced stable QoL 
      relative to pre-treatment levels on long-term follow-up. Further studies are 
      needed to characterise patients at greatest risk for decreased QoL.
CI  - Copyright (c) 2023. Published by Elsevier Ltd.
FAU - Cruz-Lim, E M
AU  - Cruz-Lim EM
AD  - University of British Columbia, British Columbia, Canada; BC Cancer - Kelowna, 
      Kelowna, British Columbia, Canada.
FAU - Mou, B
AU  - Mou B
AD  - University of British Columbia, British Columbia, Canada; BC Cancer - Kelowna, 
      Kelowna, British Columbia, Canada.
FAU - Baker, S
AU  - Baker S
AD  - University of British Columbia, British Columbia, Canada; BC Cancer - Surrey, 
      Surrey, British Columbia, Canada.
FAU - Arbour, G
AU  - Arbour G
AD  - University of British Columbia, British Columbia, Canada.
FAU - Stefanyk, K
AU  - Stefanyk K
AD  - University of British Columbia, British Columbia, Canada.
FAU - Jiang, W
AU  - Jiang W
AD  - University of British Columbia, British Columbia, Canada; BC Cancer - Surrey, 
      Surrey, British Columbia, Canada.
FAU - Liu, M
AU  - Liu M
AD  - University of British Columbia, British Columbia, Canada; BC Cancer - Vancouver, 
      Vancouver, British Columbia, Canada.
FAU - Bergman, A
AU  - Bergman A
AD  - University of British Columbia, British Columbia, Canada; BC Cancer - Vancouver, 
      Vancouver, British Columbia, Canada.
FAU - Schellenberg, D
AU  - Schellenberg D
AD  - University of British Columbia, British Columbia, Canada; BC Cancer - Surrey, 
      Surrey, British Columbia, Canada.
FAU - Alexander, A
AU  - Alexander A
AD  - University of British Columbia, British Columbia, Canada; BC Cancer - Victoria, 
      Victoria, British Columbia, Canada.
FAU - Berrang, T
AU  - Berrang T
AD  - University of British Columbia, British Columbia, Canada; BC Cancer - Victoria, 
      Victoria, British Columbia, Canada.
FAU - Bang, A
AU  - Bang A
AD  - University of British Columbia, British Columbia, Canada; BC Cancer - Vancouver, 
      Vancouver, British Columbia, Canada.
FAU - Chng, N
AU  - Chng N
AD  - BC Cancer - Prince George, Prince George, British Columbia, Canada.
FAU - Matthews, Q
AU  - Matthews Q
AD  - BC Cancer - Prince George, Prince George, British Columbia, Canada.
FAU - Carolan, H
AU  - Carolan H
AD  - University of British Columbia, British Columbia, Canada; BC Cancer - Vancouver, 
      Vancouver, British Columbia, Canada.
FAU - Hsu, F
AU  - Hsu F
AD  - University of British Columbia, British Columbia, Canada; BC Cancer - Abbotsford, 
      Abbotsford, British Columbia, Canada.
FAU - Miller, S
AU  - Miller S
AD  - University of British Columbia, British Columbia, Canada; BC Cancer - Prince 
      George, Prince George, British Columbia, Canada.
FAU - Atrchian, S
AU  - Atrchian S
AD  - University of British Columbia, British Columbia, Canada; BC Cancer - Kelowna, 
      Kelowna, British Columbia, Canada.
FAU - Chan, E
AU  - Chan E
AD  - University of British Columbia, British Columbia, Canada; BC Cancer - Kelowna, 
      Kelowna, British Columbia, Canada.
FAU - Ho, C
AU  - Ho C
AD  - University of British Columbia, British Columbia, Canada; BC Cancer - Surrey, 
      Surrey, British Columbia, Canada.
FAU - Mohamed, I
AU  - Mohamed I
AD  - University of British Columbia, British Columbia, Canada; BC Cancer - Kelowna, 
      Kelowna, British Columbia, Canada.
FAU - Lin, A
AU  - Lin A
AD  - University of British Columbia, British Columbia, Canada; BC Cancer - Kelowna, 
      Kelowna, British Columbia, Canada.
FAU - Huang, V
AU  - Huang V
AD  - BC Cancer - Surrey, Surrey, British Columbia, Canada.
FAU - Mestrovic, A
AU  - Mestrovic A
AD  - BC Cancer - Vancouver, Vancouver, British Columbia, Canada.
FAU - Hyde, D
AU  - Hyde D
AD  - University of British Columbia, British Columbia, Canada; BC Cancer - Kelowna, 
      Kelowna, British Columbia, Canada.
FAU - Lund, C
AU  - Lund C
AD  - University of British Columbia, British Columbia, Canada; BC Cancer - Surrey, 
      Surrey, British Columbia, Canada.
FAU - Pai, H
AU  - Pai H
AD  - University of British Columbia, British Columbia, Canada; BC Cancer - Victoria, 
      Victoria, British Columbia, Canada.
FAU - Valev, B
AU  - Valev B
AD  - University of British Columbia, British Columbia, Canada; BC Cancer - Victoria, 
      Victoria, British Columbia, Canada.
FAU - Lefresne, S
AU  - Lefresne S
AD  - University of British Columbia, British Columbia, Canada; BC Cancer - Vancouver, 
      Vancouver, British Columbia, Canada.
FAU - Tyldesley, S
AU  - Tyldesley S
AD  - University of British Columbia, British Columbia, Canada; BC Cancer - Vancouver, 
      Vancouver, British Columbia, Canada.
FAU - Olson, R
AU  - Olson R
AD  - University of British Columbia, British Columbia, Canada; BC Cancer - Prince 
      George, Prince George, British Columbia, Canada. Electronic address: 
      Rolson2@bccancer.bc.ca.
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Multicenter Study
DEP - 20231203
PL  - England
TA  - Clin Oncol (R Coll Radiol)
JT  - Clinical oncology (Royal College of Radiologists (Great Britain))
JID - 9002902
SB  - IM
MH  - Humans
MH  - British Columbia
MH  - Lymphatic Metastasis
MH  - Pain/etiology
MH  - Prospective Studies
MH  - *Quality of Life
MH  - *Radiosurgery/adverse effects/methods
OTO - NOTNLM
OT  - Oligometastasis
OT  - quality of life
OT  - stereotactic ablative radiotherapy
OT  - stereotactic body radiotherapy
EDAT- 2023/12/13 06:42
MHDA- 2024/02/19 06:42
CRDT- 2023/12/13 01:17
PHST- 2023/09/11 00:00 [received]
PHST- 2023/11/11 00:00 [revised]
PHST- 2023/11/28 00:00 [accepted]
PHST- 2024/02/19 06:42 [medline]
PHST- 2023/12/13 06:42 [pubmed]
PHST- 2023/12/13 01:17 [entrez]
AID - S0936-6555(23)00456-9 [pii]
AID - 10.1016/j.clon.2023.11.041 [doi]
PST - ppublish
SO  - Clin Oncol (R Coll Radiol). 2024 Mar;36(3):148-156. doi: 
      10.1016/j.clon.2023.11.041. Epub 2023 Dec 3.